Hi Timomo. That was the original number analysts estimated for Trofinetide, Neuren’s FDA approved drug. As it turns out the actual drug cost will be $375k per patient per annum. Hence the daily re-rate upwards for Neuren.
Pricing for BOT will be similar to Qbrexa or at a slight premium to it. This has been stated by Howe in the latest investor video.
Ann: Investor Presentation, page-33
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 470483 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 33000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |